Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
Globe Newswire•09/11/2026•16:01 ET
1
Key Highlights
- ➤Cash $565.2 million supports operations at least into mid-2029
- ➤SEP-479 Phase 1 SAD/MAD data expected in Q1 2027
- ➤SEP-204 Phase 1 trial planned for Q1 2027 after preclinical selection
- ➤Q3 revenue $18.9 million, down from $21.5 million year over year
- ➤Q3 net loss $26.6 million versus $8.2 million net income year earlier
Expert Statements
Jeffrey Finer, Chief Executive Officer and Co-founder of Septerna
“We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves’ disease and thyroid eye disease”
Jeffrey Finer, Chief Executive Officer and Co-founder of Septerna
“With Phase 1 data for SEP-479 and the initiation a Phase 1 trial of SEP-204 expected in the first quarter of 2027, we are moving closer to realizing our ambition to translate our GPCR expertise into differentiated oral medicines for patients with significant unmet needs.”
Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027
Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027
Get started
Create a free account to read the full story.